COMMUNIQUÉS West-GlobeNewswire

TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting
22/02/2019
NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the final Phase 2 data from the multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti [...]
BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
22/02/2019
Phase 2 Open-Label Trial of Autologous MSC-NTF Cell Therapy (NurOwn®) in Progressive MS Patients will Begin Enrollment in Early 2019 NEW YORK and CLEVELAND, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics [...]
Vectra® Study Published in the Journal Current Medical Research & Opinion
22/02/2019
Vectra Test Significantly Outperforms DAS28-CRP and CRP and Is the Best Predictor of Joint Damage in Patients with Rheumatoid Arthritis SALT LAKE CITY, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: [...]
BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference
22/02/2019
CAMBRIDGE, Mass. and BEIJING, China, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development
22/02/2019
CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment of [...]
R1 RCM Reports Fourth Quarter and Full Year 2018 Results
22/02/2019
CHICAGO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management services to healthcare providers, today announced results for the three months and [...]
Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
22/02/2019
-- Ended 2018 with a cash position of $449.0 million -- -- Phase 2 trials of M281 in myasthenia gravis (MG) and hemolytic disease of the fetus and newborn (HDFN) underway; First healthy volunteer dosed in Phase 1/2 [...]
HMS Reports Fourth Quarter and Full Year 2018 Financial Results
22/02/2019
Record 4Q’18 Total Revenue of $155.8 Million and Record Full Year 2018 Revenue of $598.3 Million 4Q’18 GAAP EPS of $0.38 Per Diluted Share, Including Discrete Tax Benefits of $0.17 Per Diluted Share 4Q’18 Adjusted EPS [...]
Announcement no. 2/2019 - Share Buyback Programme
22/02/2019
Announcement no. 2/2019 22 February 2019 Coloplast initiates the second part of the DKK 1bn share buy-back programme Coloplast A/S is initiating the second part of the share buy-back programme totalling up to DKK 1bn, [...]
BioPorto Announces Annual Report 2018
22/02/2019
February 22, 2019 Announcement no. 2 Annual Report 2018 Full speed ahead Highlights from the Annual Report 2018 Revenue growth of 80% from sales of The NGAL Test™ in U.S. and 18% in rest of the world in 2018 Total [...]
Novo Nordisk: Notice for the Annual General Meeting of Novo Nordisk A/S
22/02/2019
Bagsværd, Denmark, 22 February 2019 - The Annual General Meeting of Novo Nordisk A/S will be held on: - Thursday 21 March 2019 at 2.00 pm (CET) at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark. The [...]
Xbrane Biopharma releases Year-end report for 2018
22/02/2019
Press release 2019-02-22 Xbrane Biopharma AB's (publ.) (" Xbrane ") Year-end report for 2018 is now available on the Company's website, www.xbrane.com . The fourth quarter 2018 in summary Revenue amounted to SEK 4,896 [...]
Notice of Nexstim Plc 2018 Full Year Results
22/02/2019
Company announcement, Helsinki, 22.02.2019 at 9am (EET) Notice of Nexstim Plc 2018 Full Year Results Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), the targeted neuromodulation company developing and [...]
Spineway :
22/02/2019
The shareholders of Spineway are invited to attend the Ordinary and Extraordinary General Shareholders’ Meeting to be held on Friday, 8 March 2019, at noon , at the company’s registered office. Notice of the meeting [...]
SPINEWAY : Modalités de mise à disposition des documents prépartoires à l’Assemblée Générale du 8 mars 2019
22/02/2019
Les actionnaires de Spineway sont invités à participer à l’Assemblée Générale Mixte qui se déroulera au siège social de la société le vendredi 8 mars 2019 à 12 heures. L’avis de réunion comportant l’ordre du jour et les [...]
NeuroSearch – Updated financial calendar for 2019
22/02/2019
Announcement 22 February 2019 NeuroSearch A/S (NEUR) hereby announces an updated company’s financial calendar for 2019. 25 February 2019 Annual Report 2018 29 April 2019 Annual General Meeting 30 August 2019 Interim [...]
ESPERITE NV (ESP) AND PBKM (FAMICORD GROUP) SIGN EXCLUSIVE AGREEMENT REGARDING POTENTIAL ACQUISITION OF CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS.
22/02/2019
Amsterdam, the Netherlands – 22 February 2019 Esperite N.V. (Euronext: ESP) and Polski Bank Komórek Macierzystych S.A. (WSE: PBKM) are pleased to announce that they have entered into an Memorandum of Understanding (MoU [...]
ObsEva SA to Participate in Upcoming Investor Conferences
22/02/2019
Geneva, Switzerland and Boston, MA – February 22, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]
Clarification Regarding Press Release Issued by Unrelated Third Party
22/02/2019
TORONTO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF, OTC: ALEAF, FRA: ARAH) (“ Aleafia Health ” or the “ Company ”), is providing an update regarding a press release (the “ Press Release ”) issued [...]

Pages